ICP MS ニヨル カンキョウ シリョウチュウ ノ コンセキ ゲンソ ノ ソクテイ 1 ICP MS ソウチ ノ サイテキ ジョウケン オヨビ ソノ ブンセキ セイド

For determination of trace elements in environmental sample by inductively coupled plasma mass spectrometry (ICP-MS), the optimum condition of ICP-MS was determined and the stability of ICP-MS and the precision of elements concentration were investigated. The optimum condition was the sampling depth : 13 mm and RF-power : 1.2 KW. The stability of ICP-MS was indicated little drift of ionic strength after plasma lighting, however, ICP-MS was stabilized after 40 minutes. The coefficient variation (CV) of analyzed element concentration by external calibration was under 3% and the precision of analysis was very high

Carbon Ion Radiotherapy for Liver Cancer

A trial of carbon ion radiotherapy (C-ion RT) for hepatocellular carcinoma (HCC) was first conducted in April 1995 at the National Institute of Radiological Sciences (NIRS) in Japan. A total of 193 patients with HCC were enrolled in this clinical trial. In the first and second phase I/II clinical trials, dose escalation studies were carried out in incremental steps of 10%, resulting in the confirmation of both the safety and efficacy of short-course regimens of 12, 8, and 4 fractions. Based on the results, a phase II clinical study with fixed fractionation, that is, 52.8 GyE/4 fractions, was performed. A total of 47 patients were treated during this phase II study, which resulted in low toxicity and attained a high local control rate (96%) for 5 years after treatment. The last clinical study was conducted from April 2003 to August 2005, with a more hypofractionated regimen of 2 fractions/2 days, in which 36 patients were safely treated within a dose escalation range from 32.0 GyE to 38.8 GyE. The 2-fraction therapy protocol is continuing under the license of Highly Advanced Medical Technology. There have been no therapy-related deaths and no severe adverse events. We conclude that, because of the low toxicity and high local control rate, C-ion RT is a promising new, radical, and minimally invasive therapeutic option for HCC

Carbon Ion Radiotherapy for Liver Cancer

A trial of carbon ion radiotherapy (C-ion RT) for hepatocellular carcinoma (HCC) was first conducted in April 1995 at the National Institute of Radiological Sciences (NIRS) in Japan. A total of 193 patients with HCC were enrolled in this clinical trial. In the first and second phase I/II clinical trials, dose escalation studies were carried out in incremental steps of 10%, resulting in the confirmation of both the safety and efficacy of short-course regimens of 12, 8, and 4 fractions. Based on the results, a phase II clinical study with fixed fractionation, that is, 52.8 GyE/4 fractions, was performed. A total of 47 patients were treated during this phase II study, which resulted in low toxicity and attained a high local control rate (96%) for 5 years after treatment. The last clinical study was conducted from April 2003 to August 2005, with a more hypofractionated regimen of 2 fractions/2 days, in which 36 patients were safely treated within a dose escalation range from 32.0 GyE to 38.8 GyE. The 2-fraction therapy protocol is continuing under the license of Highly Advanced Medical Technology. There have been no therapy-related deaths and no severe adverse events. We conclude that, because of the low toxicity and high local control rate, C-ion RT is a promising new, radical, and minimally invasive therapeutic option for HCC.2nd NIRS-ETOILE Joint Symposium on Carbon Ion Therap

Efficacy and safety of short-course carbon ion radiotherapy for elderly hepatocellular carcinoma patients

Purpose: Since 1995, carbon ion radiotherapy (C-ion RT) has been performed for treatment of HCC, and clinical trials were initiated at the National Institute of Radiological Science (NIRS). This study was conducted to evaluate the efficacy and safety of C-ion RT in elderly patients with hepatocellular carcinoma (HCC).\nMaterials and methods: Sixty-four patients with HCC, including 24 elderly (aged >70 years) patients, were treated with C-ion RT of 52.8GyE in 4 fractions between April 2000 and March 2003. Baseline characterstics, local control/survival rates, and adverse events were compared between elderly and non-elderly patients (≤70 years old vs. >70 years old).\nResults: There were no significant differences in UICC clinical stage and Child-Pugh grade between the 2 groups. No hepatic failure resulting from the therapy and no treatment-related death occurred. The cumulative overall survival rates in the elderly group were 58.3% at 3 years and 29.2% at 5 years, which was equivalent to the non-elderly group. The local control rates after both 3 and 5 years were 95.8% and 92.4% in the elderly group and the non-elderly group, respectively. There were no significant differences between the 2 groups.\nConclusions: Short-course C-ion RT for the patients with HCC appears to be safe and effective in elderly patients, as well as non-elderly patients.The 22nd Congress of the Asian Pacific Association for the Study of the Live

Carbon Ion Radiotherapy for Liver Cancer

The objective of this paper is to present a summary of a clinical study on carbon ion radiotherapy (C-ion RT) for hepatocellular carcinoma (HCC) conducted from April 1995 to August 2005 at the Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, in Japan. A total of 193 patients with HCC were enrolled in the clinical trial of carbon ion beams. In the first and second phase I/II clinical trials, dose escalation experiments were carried out in incremental steps of 10%, resulting in the confirmation of both the safety and efficacy of short-course regimens of 12, 8 and 4 fractions. Based on the results, a phase II clinical study with fixed fractionation, that is, 52.8 GyE/4 fractions, was performed. A total of 47 patients were treated during this phase II study, which resulted in low toxicity and attained a high local control rate (96%) for 5 years after treatment. The last clinical study was conducted from April 2003 to August 2005 with a more hypofractionated regimen of 2 fractions/2 days, in which 36 patients were safely treated within a dose escalation range from 32.0 GyE to 38.8 GyE. The 2-fraction therapy protocol is continuing under the license of Highly Advanced Medical Technology. There have been no therapy-related deaths and no severe adverse events. We can conclude that, because of the low toxicity and high local control rate, C-ion RT has a promising potential as a new, radical, and minimally invasive therapeutic option for HCC